on Theralase Technologies Inc. (isin : CA88337V1004)
Rutherrin® Increases Efficacy of Chemotherapy
TORONTO, ON / ACCESSWIRE / June 12, 2024 / Theralase® Technologies Inc. announced significant preclinical findings regarding its lead drug formulation, Rutherrin®. The data suggest Rutherrin® can enhance chemotherapy efficacy and reduce multidrug resistance (MDR).
Multidrug resistance is a common issue in cancer treatment, often due to the overexpression of ATP-Binding Cassette (ABC) transporters. These transporters pump chemotherapeutic drugs out of cancer cells, diminishing their effectiveness. Rutherrin® appears to inhibit this efflux, allowing for higher intracellular drug accumulation.
Various chemotherapeutic drugs showed increased retention and cell kill rates when combined with Rutherrin®. Additionally, mouse models demonstrated delayed tumor progression and improved survival rates with Rutherrin® plus Vinblastine.
Dr. Arkady Mandel stated that adding Rutherrin® could maintain or enhance chemotherapy effectiveness by modulating drug efflux. CEO Roger DuMoulin-White highlighted Rutherrin®’s potential to optimize cancer treatments and overcome MDR challenges.
R. H.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Theralase Technologies Inc. news